Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Abstract We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms when eligibility crit...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2022-10-01
|
| סדרה: | npj Precision Oncology |
| גישה מקוונת: | https://doi.org/10.1038/s41698-022-00317-0 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
